WEBULL
News
CRRTF
0.350
NaN%
--
Crescita Therapeutics GAAP EPS of $0.04, revenue of $5.39M
Seeking Alpha · 11/05 18:36
Crescita Reports Third Quarter 2025 Results
Barchart · 11/05 06:30
Weekly Report: what happened at CRRTF last week (0908-0912)?
Weekly Report · 09/15 11:00
Weekly Report: what happened at CRRTF last week (0901-0905)?
Weekly Report · 09/08 11:02
Weekly Report: what happened at CRRTF last week (0825-0829)?
Weekly Report · 09/01 10:58
Weekly Report: what happened at CRRTF last week (0818-0822)?
Weekly Report · 08/25 11:07
Weekly Report: what happened at CRRTF last week (0811-0815)?
Weekly Report · 08/18 11:00
Weekly Report: what happened at CRRTF last week (0804-0808)?
Weekly Report · 08/11 11:06
Weekly Report: what happened at CRRTF last week (0728-0801)?
Weekly Report · 08/04 11:09
Weekly Report: what happened at CRRTF last week (0721-0725)?
Weekly Report · 07/28 11:10
Weekly Report: what happened at CRRTF last week (0714-0718)?
Weekly Report · 07/21 11:00
Weekly Report: what happened at CRRTF last week (0707-0711)?
Weekly Report · 07/14 11:09
Weekly Report: what happened at CRRTF last week (0630-0704)?
Weekly Report · 07/07 11:01
Weekly Report: what happened at CRRTF last week (0623-0627)?
Weekly Report · 06/30 11:07
Weekly Report: what happened at CRRTF last week (0616-0620)?
Weekly Report · 06/23 11:00
Weekly Report: what happened at CRRTF last week (0609-0613)?
Weekly Report · 06/16 11:07
Weekly Report: what happened at CRRTF last week (0602-0606)?
Weekly Report · 06/09 11:08
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Barchart · 06/05 07:17
Weekly Report: what happened at CRRTF last week (0526-0530)?
Weekly Report · 06/02 11:16
Weekly Report: what happened at CRRTF last week (0519-0523)?
Weekly Report · 05/26 11:15
More
Webull provides a variety of real-time CRRTF stock news. You can receive the latest news about Crescita Therape through multiple platforms. This information may help you make smarter investment decisions.
About CRRTF
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment is engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. The Manufacturing and Services segment is engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.